淋病奈瑟菌抗生素耐药性的持续演变:过去、现在与未来威胁
淋病是全球公共卫生威胁,淋病奈瑟菌对 successive 类抗生素耐药,迫使国内外治疗指南定期更新;即使停用某类抗生素,耐药性常保留,菌株随时间变为多重耐药。未来需多学科全球策略,包括可及诊断、国际耐药监测、新抗生素研发及抗菌药物管理。
要点
- 淋病奈瑟菌对多种抗生素产生耐药,导致治疗指南定期更新。
- 即使抗生素不再经验性使用,耐药性仍可保留,菌株可变为多重耐药。
- 确保淋病可治疗需全球多学科合作,包括诊断、监测、新药与抗菌药物管理。
核心结论
- 淋病奈瑟菌对 successive 类抗生素耐药,未来需多学科全球策略确保淋病可治疗。
研究设计与样本
- 综述,检索范围未在原文中明确描述。
主要发现
- 淋病奈瑟菌对 successive 类抗生素产生耐药,迫使国内外治疗指南定期更新。
- 即使特定抗生素不再经验性用于治疗淋病,淋病奈瑟菌常保留耐药性,菌株随时间变为多重耐药。
关键数值与推荐
- 原文未汇总具体耐药率、阈值或推荐条款。
临床怎么用
- 未来需多学科全球合作,包括提供广泛可及且负担得起的诊断检测、稳健的国际耐药监测、新抗生素研发及加强抗菌药物管理以优化新旧抗菌药物使用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gonorrhoea constitutes a global public health threat. Although a range of antibiotics have been available to treat gonococcal infections for more than 80 years, Neisseria gonorrhoeae has shown remarkable versatility in its ability to develop resistance to successive classes of drugs. As a result, national and international treatment guidelines have had to be regularly updated to take account of increases in the prevalence of gonococcal strains resistant to recommended antibiotics. Even when particular antibiotics are no longer empirically used to treat gonorrhoea, N. gonorrhoeae often retains resistance, with strains becoming MDR over time. Future efforts to ensure gonorrhoea remains a treatable infection will require a multidisciplinary global approach including efforts to provide widely available and affordable diagnostic testing, robust international surveillance of resistance, and the development of new antibiotics coupled with enhanced antimicrobial stewardship to ensure optimal use of both new and older antimicrobial agents.
引用
- Fifer H, Johnson A. The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment. J Antimicrob Chemother. 2025. PMID: 40205910. doi:10.1093/jac/dkaf109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。